Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.69 |
| ▸ | TDO2 | P48775 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520579 | 0.85 | IDO1 (0.79) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL2518277 | 0.84 | IDO1 (0.74) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL2519342 | 0.82 | IDO1 (0.74) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL19808082 | 0.82 | IDO1 (1.00) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL149781 | 0.82 | IDO1 (1.00) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL2516661 | 0.81 | IDO1 (0.69) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL2512553 | 0.79 | IDO1 (1.00) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL2514020 | 0.78 | HTT (0.73) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL17595459 | 0.78 | IDO1 (0.42) | IDO1TDO2HTTGFERLMNA | |
| SCHEMBL19654572 | 0.78 | IDO1 (0.42) | IDO1TDO2HTTGFERLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183082-B2 | PET probes of radiofluorinated carboximidamides for IDO-targeted imaging | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340758-A1 | PET PROBES OF RADIOFLUORINATED CARBOXIMIDAMIDES FOR IDO-TARGETED IMAGING | H LEE MOFFITT CANCER CT & RES (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016040458-A2 | PET PROBES OF RADIOFLUORINATED CARBOXIMIDAMIDES FOR IDO-TARGETED IMAGING | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183082-B2 | PET probes of radiofluorinated carboximidamides for IDO-targeted imaging | IDO1, IDO2, KMO | IDO1 1/4885TDO2 6/4885HTT 370/4885 |
| US-20170340758-A1 | PET PROBES OF RADIOFLUORINATED CARBOXIMIDAMIDES FOR IDO-TARGETED IMAGING | IDO1, IDO2, IDH1 | IDO1 1/4885TDO2 19/4885HTT 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.